Fluconazole | Mikosist capsules 150 mg, 1 pc.

Release form

Capsules

Packing

1 pc

Indications

cryptococcosis - cryptococcal meningitis cryptococcal infections of the lungs and skin cryptococcal sepsis prevention of relapses of cryptococcosis in AIDS patients with organ transplantation or other cases of

immunodeficiency, generalized candidiasis, candidiasis, and candida infection respiratory and urinary tract), incl. in patients receiving a course of cytostatic or immunosuppressive therapy, as well as in the presence of other factors predisposing to the development of candidiasis, treatment and prevention of

candidiasis of the mucous membranes of the oral cavity, including atrophic candidiasis of the oral cavity associated with wearing dentures, pharynx, esophagus and non-invasive bronchopulmonary infections, candiduria

genital candidiasis - vaginal (acute or chronic relapsing form) candida balanitis (capsules)

prevention of fungal infections in patients with malignant neoplasms who are predisposed to such infections as a result of chemotherapy with cytostatics or radiation therapy prevention of recurrence of oropharyngeal candidiasis in patients with oropharyngeal candidiasis skin, including mycoses of the trunk, inguinal region

capsules: pityriasis versicolor, onychomycosis, foot mycoses

deep endemic mycoses, including coccidioidosis, paracoccidioidosis and histoplasmosis in patients with normal immunity.

Contraindications

hypersensitivity to fluconazole, other components of the drug, or other structured azole compounds

, the simultaneous use of terfenadine (with the constant use of fluconazole at a dose of 400 mg / day or higher) and cisapride, because both drugs lengthen the QT interval and increase the risk of severe cardiac arrhythmias

simultaneous use of astemizole

lactose intolerance, lactase deficiency, glucose-galactose malabsorption (capsules)

lactation period.

Caution: hepatic and / or renal failure rash on the background of the use of fluconazole in patients with superficial fungal infection and invasive / systemic fungal infections, the simultaneous use of fluconazole with rifabutin or other drugs metabolized by the P450 cytochrome system, the simultaneous use of terfenadine and fluconazole in a dose of less than 400 mg / day proarrhythmogenic conditions in patients with multiple risk factors (organic heart disease, electrolyte imbalance, one belt intake of drugs causing arrhythmias) patients with intolerance to acetylsalicylic acid pregnancy.

Use during pregnancy and lactation

The use of fluconazole during pregnancy is possible only if the potential benefit to the mother outweighs the risk to the fetus.

Fluconazole is determined in breast milk at the same concentration as in plasma, so its administration during lactation is contraindicated.

Ingredients

1 capsule contains:

Active ingredient:

fluconazole 150 mg

Excipients:

silicon dioxide colloidal

magnesium stearate

talc

um powder



Side effects

From the digestive system: nausea, vomiting, diarrhea, flatulence, abdominal pain, taste change, impaired liver function (hyperbilirubinemia, increased activity of hepatic transaminases, alkaline phosphatase, jaundice, hepatitis, hepatocellular necrosis, including fatal).

From the nervous system: headache, dizziness, cramps.

From the hemopoietic organs: leukopenia, thrombocytopenia, neutropenia, agranulocytosis.

Allergic reactions: skin rash, erythema multiforme exudative (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), anaphylactoid reactions (including angioedema, facial edema, urticaria, pruritus), bronchial asthma (more often with intolerance to acetylsalicylic acid).

On the part of the CCC: an increase in the duration of the QT interval on the ECG, ventricular fibrillation / flutter.

Other: impaired renal function, alopecia, hypercholesterolemia, hypertriglyceridemia, hypokalemia.

Drug Interaction

Anticoagulants. Patients receiving fluconazole and indirect coumarin anticoagulants need careful control of PV as it may increase.

Sulfonylureas. Fluconazole, when co-administered, may lengthen the T1 / 2 sulfonylurea derivatives, therefore, when used together, consideration should be given to the possibility of developing hypoglycemia.

Phenytoin. Concomitant administration of fluconazole and phenytoin may be accompanied by a clinically relevant increase in the concentration of phenytoin, which requires a reduction in its dose.

Rifampicin. When concurrent administration of rifampicin and fluconazole decreases Cmax and T1 / 2 of the latter, therefore, if necessary, the combined dose should increase the dose of fluconazole.

Rifabutin. The combined use of fluconazole and rifabutin is accompanied by an increase in serum concentration of the latter, the development of uveitis is possible.

Cyclosporine. When fluconazole and cyclosporine are co-administered, it is recommended to control the concentration of the latter as it may increase.

Terfenadine. Given the emergence of serious, life-threatening events, arrhythmias in patients taking antifungal agents - azole derivatives in combination with terfenadine, their co-administration is contraindicated.

Cisapride. With concomitant administration of fluconazole and cisapride, adverse events from the heart have been reported, including ventricular tachycardia paroxysms. Simultaneous administration is contraindicated.

Zidovudine. When combined with fluconazole, it is possible to increase the concentration of zidovudine in the blood plasma. Patients taking this combination should be observed to identify side effects of zidovudine.

Theophylline. Fluconazole administration leads to a decrease in the average clearance rate of theophylline from the blood plasma, therefore increasing the risk of the toxic effect of theophylline and its overdose.

Midazolam. Concomitant use of fluconazole and midazolam leads to a significant increase in the latter's plasma concentration and the risk of psychomotor reactions.

Hydrochlorothiazide. Concomitant administration of fluconazole and hydrochlorothiazide increases the concentration of fluconazole in blood plasma by 40%.

Tacrolimus. Concomitant administration of fluconazole and tacrolimus increases the serum concentration of the latter, which increases the risk of nephrotoxicity.

Caution should be exercised when using fluconazole in patients receiving other drugs metabolised by the cytochrome P450 system.

Overdose

Symptoms: nausea, vomiting, diarrhea in severe cases, convulsions, hallucinations, paranoid behavior may occur.

Treatment: symptomatic (gastric lavage, forced diuresis, hemodialysis). After a 3-hour hemodialysis session, the concentration of fluconazole in the blood plasma decreases by about 50%.

Storage conditions

At a temperature of 15–30 РC.

Expiration

5 Chron

Deystvuyuschee substances

Fluconazole

dosage form

dosage form

capsules

Gedeon Richter Vengriya